Ingrid G. Rekeland
Bergen, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Charting the circulating proteome in ME/CFS using cross-system profiling to uncover mechanistic insights.
Journal: Cell reports. Medicine
Published: May 28, 2025
Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot study.
Journal: Frontiers in medicine
Published: April 07, 2025
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Journal: PloS one
Published: July 05, 2023
Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci.
Journal: Brain, behavior, and immunity
Published: June 23, 2021
A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome.
Journal: JCI insight
Published: March 09, 2021
Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Results From Open-Label Cyclophosphamide Intervention Study.
Journal: Frontiers in medicine
Published: December 16, 2020
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.
Journal: Frontiers in medicine
Published: October 14, 2019
B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Annals of internal medicine
Published: April 02, 2019
Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Journal: Clinical therapeutics
Published: June 22, 2018
Last Updated: 09/26/2026